R H Swartz1, S E Black. 1. Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. rick.swartz@utoronto.ca
Abstract
BACKGROUND: The anterior-medial thalamus (AMT), which is associated with memory processing, is severely affected by Alzheimer's disease pathology and, when damaged, can be the sole cause of dementia. OBJECTIVE: To assess the frequency of magnetic resonance imaging (MRI) hyperintensities affecting the AMT, and their relationship with sudden cognitive decline. METHODS: 205 consecutive participants from a university cognitive neurology clinic underwent clinical evaluation, neuropsychological testing and quantitative MRI. RESULTS: AMT hyperintensities >5 mm3 occurred in 0 of 34 normal controls but were found in 5 of 30 (17%) participants with cognitive impairment with no dementia (CIND), 9 of 109 (8%) patients with probable Alzheimer's disease, 7 of 17 (41%) with mixed disease and 8 of 15 (53%) with probable vascular dementia (VaD). AMT hyperintensities occurred more often in participants with stepwise decline than in those with slow progression (chi2 = 31.7; p<0.001). Of the 29 people with AMT hyperintensities, those with slow progression had smaller medial temporal width (p<0.001) and smaller anterior-medial thalamic hyperintensities (p<0.001). In a logistic regression model, both variables were significant, and the pattern of decline was correctly classified in 86% of the sample (Cox and Snell R2 = 0.56; p<0.001). Those with AMT hyperintensities >55 mm3 were likely to have stepwise decline in cognitive function regardless of medial temporal lobe width; in contrast, those with smaller AMT hyperintensities showed a stepwise decline only in the absence of medial temporal lobe atrophy. All patients with VaD had left-sided AMT hyperintensities, whereas those with CIND had right-sided AMT hyperintensities. CONCLUSIONS: AMT hyperintensities >55 mm3 probably result in symptomatic decline, whereas smaller lesions may go unrecognised by clinicians and radiologists. Only half of those with AMT hyperintensities had diagnoses of VaD or mixed disease; the other AMT hyperintensities occurred in patients diagnosed with Alzheimer's disease or CIND. These silent hyperintensities may nevertheless contribute to cognitive dysfunction. AMT hyperintensities may represent a major and under-recognised contributor to cognitive impairment.
BACKGROUND: The anterior-medial thalamus (AMT), which is associated with memory processing, is severely affected by Alzheimer's disease pathology and, when damaged, can be the sole cause of dementia. OBJECTIVE: To assess the frequency of magnetic resonance imaging (MRI) hyperintensities affecting the AMT, and their relationship with sudden cognitive decline. METHODS: 205 consecutive participants from a university cognitive neurology clinic underwent clinical evaluation, neuropsychological testing and quantitative MRI. RESULTS: AMT hyperintensities >5 mm3 occurred in 0 of 34 normal controls but were found in 5 of 30 (17%) participants with cognitive impairment with no dementia (CIND), 9 of 109 (8%) patients with probable Alzheimer's disease, 7 of 17 (41%) with mixed disease and 8 of 15 (53%) with probable vascular dementia (VaD). AMT hyperintensities occurred more often in participants with stepwise decline than in those with slow progression (chi2 = 31.7; p<0.001). Of the 29 people with AMT hyperintensities, those with slow progression had smaller medial temporal width (p<0.001) and smaller anterior-medial thalamic hyperintensities (p<0.001). In a logistic regression model, both variables were significant, and the pattern of decline was correctly classified in 86% of the sample (Cox and Snell R2 = 0.56; p<0.001). Those with AMT hyperintensities >55 mm3 were likely to have stepwise decline in cognitive function regardless of medial temporal lobe width; in contrast, those with smaller AMT hyperintensities showed a stepwise decline only in the absence of medial temporal lobe atrophy. All patients with VaD had left-sided AMT hyperintensities, whereas those with CIND had right-sided AMT hyperintensities. CONCLUSIONS: AMT hyperintensities >55 mm3 probably result in symptomatic decline, whereas smaller lesions may go unrecognised by clinicians and radiologists. Only half of those with AMT hyperintensities had diagnoses of VaD or mixed disease; the other AMT hyperintensities occurred in patients diagnosed with Alzheimer's disease or CIND. These silent hyperintensities may nevertheless contribute to cognitive dysfunction. AMT hyperintensities may represent a major and under-recognised contributor to cognitive impairment.
Authors: António J Bastos Leite; Elisabeth C W van Straaten; Philip Scheltens; Geert Lycklama; Frederik Barkhof Journal: Stroke Date: 2004-01-15 Impact factor: 7.914
Authors: Christian Bocti; Richard H Swartz; Fu-Qiang Gao; Demetrios J Sahlas; Pearl Behl; Sandra E Black Journal: Stroke Date: 2005-09-22 Impact factor: 7.914
Authors: Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245
Authors: G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman Journal: Neurology Date: 1993-02 Impact factor: 9.910
Authors: Perminder Sachdev; Raj Kalaria; John O'Brien; Ingmar Skoog; Suvarna Alladi; Sandra E Black; Deborah Blacker; Dan G Blazer; Christopher Chen; Helena Chui; Mary Ganguli; Kurt Jellinger; Dilip V Jeste; Florence Pasquier; Jane Paulsen; Niels Prins; Kenneth Rockwood; Gustavo Roman; Philip Scheltens Journal: Alzheimer Dis Assoc Disord Date: 2014 Jul-Sep Impact factor: 2.703
Authors: Michael J Firbank; Louise M Allan; Emma J Burton; Robert Barber; John T O'Brien; Raj N Kalaria Journal: J Neurol Neurosurg Psychiatry Date: 2011-11-23 Impact factor: 10.154
Authors: Arunima Kapoor; Robert Bartha; Sandra E Black; Michael Borrie; Morris Freedman; Fuqiang Gao; Nathan Herrmann; Jennifer Mandzia; Miracle Ozzoude; Joel Ramirez; Christopher J M Scott; Sean Symons; Corinne E Fischer; Andrew Frank; Dallas Seitz; Michael Uri Wolf; Nicolaas Paul L G Verhoeff; Gary Naglie; William Reichman; Mario Masellis; Sara B Mitchell; David F Tang-Wai; Maria Carmela Tartaglia; Sanjeev Kumar; Bruce G Pollock; Tarek K Rajji; Elizabeth Finger; Stephen H Pasternak; Richard H Swartz Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472